Holen Sie sich die Stockscreener-App
35.16
4.77%
1.60
Handel nachbörslich:
35.49
0.33
+0.94%
Schlusskurs vom Vortag:
$33.56
Offen:
$34.6
24-Stunden-Volumen:
60,928
Relative Volume:
2.62
Marktkapitalisierung:
$211.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-15.29
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
+10.15%
1M Leistung:
+17.16%
6M Leistung:
+58.24%
1J Leistung:
+4,783%
1-Tages-Spanne:
$33.54
$36.11
1-Wochen-Bereich:
$31.84
$36.20
52-Wochen-Spanne:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
35.16 | 211.01M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
Monopar Therapeutics (NASDAQ:MNPR) Trading 0.4% Higher – Time to Buy? - Defense World
Monopar Therapeutics Inc. and Excel Diagnostics and Nuclear Oncology Center Announce Expanded Access Program for Mnpr-101-Zr and Mnpr-101-Lu in Advanced Cancers - MarketScreener
Monopar and EDNOC Announce Expanded Access Program for MNPR-101- - GuruFocus
Monopar Therapeutics (MNPR) Gains FDA Nod for Expanded Access Program | MNPR Stock News - GuruFocus
Monopar Therapeutics Announces FDA Authorization for Expanded Access Program of Investigational Agents MNPR-101-Zr and MNPR-101-Lu in Collaboration with Excel Diagnostics - Nasdaq
FDA Greenlights Expanded Access: New Treatment Hope for Breast, Pancreatic, and Colorectal Cancer Patients - Stock Titan
Learn to Evaluate (MNPR) using the Charts - news.stocktradersdaily.com
Head to Head Contrast: Monopar Therapeutics (NASDAQ:MNPR) vs. Climb Bio (NASDAQ:CLYM) - Defense World
Monopar Therapeutics (MNPR) Gains Buy Rating and $71 Price Targe - GuruFocus
Monopar Therapeutics (MNPR) Gains Buy Rating and $71 Price Target | MNPR Stock News - GuruFocus
Monopar Therapeutics (MNPR) Set for Inclusion in Russell Indexes - GuruFocus
Monopar Therapeutics (MNPR) Set for Inclusion in Russell Indexes | MNPR Stock News - GuruFocus
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - The Manila Times
Monopar joins Russell 3000 and 2000 indexes, growth acknowledged By Investing.com - Investing.com UK
Monopar Therapeutics Added to Russell Indexes, Gains Access to $10.6T Benchmark Assets - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
(MNPR) Trading Advice - news.stocktradersdaily.com
Research Analysts Offer Predictions for MNPR Q2 Earnings - Defense World
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Globe and Mail
Monopar Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Monopar (MNPR) Projects Financial Stability Through 2026 | MNPR Stock News - GuruFocus
Monopar Therapeutics reports Q1 EPS (38c), consensus (57c) - TipRanks
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics SEC 10-Q Report - TradingView
2,037 Shares in Monopar Therapeutics Inc. (NASDAQ:MNPR) Acquired by JPMorgan Chase & Co. - Defense World
(MNPR) Proactive Strategies - news.stocktradersdaily.com
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wi - GuruFocus
Monopar Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Monopar Therapeutics Highlights ALXN1840 Data at EASL 2025 - TipRanks
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wilson Disease | MNPR Stock News - GuruFocus
Monopar Therapeutics (MNPR) Expected to Announce Quarterly Earnings on Thursday - Defense World
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 | MNPR Stock News - GuruFocus
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 - The Manila Times
Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World
Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Insider Monkey
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times
Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
(MNPR) Investment Analysis - news.stocktradersdaily.com
Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com
(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com
Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks
Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):